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OBJECTIVES: to explore the effects of patient self-testing (PST) of oral anticoagula-
tion therapy (OAT) by CoaguChek® XS System compared to standard available care
(laboratory testing) for selected group of patients. METHODS: Health Economy
Model (HECON), using Cost-Effectiveness Analysis (CEA), complemented by Bud-
get-Impact Analysis (BIA) on public health insurance coverage in Slovakia. We
searched MEDLINE, Cochrane and available grey literature (Industrial Sources and
Expert Opinions) for meta analyses, systematic reviews, economic evaluation stud-
ies and health technology reports on PST of OAT. Outcomes analyzed were feasi-
bility and accuracy of PST, thromboembolic events, hemorrhagic complications
and mortality. Real-world data from General Health Insurance, Inc. were used for
costs associated with corresponding diagnoses, complications and management of
patients on OAT, including full cohort of patients (n100, average age of 63 years)
on PST. Markov Model (life time horizon) for OAT patient management was devel-
oped, comparing PST with standard care. Outcomes observed were major throm-
boembolic events, major hemorrhagic complications and mortality. Payer perspec-
tive and direct healthcare costs only, associated with OAT management were
considered in CEA and BIA for diagnosis subgroups. Discount rate of 5% was used
for costs as well as outcomes. Sensitivity analysis for major complications was
performed. RESULTS: CEA for PST vs. standard care associated with OAT shows
that intervention is cost-effective (dominant) for all diagnosis subgroups. Net costs
(BIA) associated with PST for expanding the existing cohort of patients 10 times
(n1000) are 1.596 mil. € in Year 1 (up to 3.579 € in Year 5). CONCLUSIONS: PST of
OAT is considered cost-effective in terms of International Normalized Ratio (INR)
regulation and safer in terms of complications. Moreover, analysis of selected sub-
populations (mitral and/or aortic mechanical heart valve implantation, aortic
and/or other aneurysm and congenital cardiovascular malformations) shows that
PST brings the most significant cost-savings especially for those OAT patient seg-
ments.
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ARE HEALTH TECHNOLOGY ASSESSMENTS OF MEDICAL DEVICES CATCHING
UP WITH PHARMACEUTICALS?
Sweeney N, Andreykiv M, Wiebinga C
Quintiles Consulting, Hoofddorp, The Netherlands
OBJECTIVES: To evaluate how HTA is applied to medical devices (MD) and to assess
whether established HTA agencies have similar influences over MD coverage and
reimbursement decisions compared to pharmaceuticals. METHODS: Manual
search of 69 HTA agencies’ websites was conducted to determine whether they
undertake MD HTAs. Of the agencies that reported MD assessments, we evaluated
the HTA process in respect to methodological approaches and influence on market
access decisions. RESULTS:The majority (49 out of 69) of HTA agencies conduct MD
assessments and make these appraisals publically available. Thirty-five of these
agencies provide reimbursement advice in their reports. In most cases recommen-
dations serve as non-mandatory guidance, aimed at helping local and national
stakeholders make informed decisions about the use of the device within their
health care system. Despite widespread use of MD evaluations, the number of
completed reviews is relatively low. Sixty percent of the agencies that performed
MD HTAs (29 out of 49) applied similar methodologies to both MD and drug
assessments. CONCLUSIONS: While the majority of HTA agencies are adding MD
assessments to their work plans, procedural pathways are not as transparent and
robust as those for pharmaceuticals. Combined with the low output of publications
this currently leads to limited application of MD HTAs to market access decisions.
However, a new system is emerging which recognizes the unique features of MD
and the distinctive level of evidence needed for regulatory approval. In future we
anticipate that market access of medical devices will be centralized under the
umbrella of existing HTA agencies. Thus, following the example of NICE, HAS and
CVZ which have established one national HTA process, with independent path-
ways within their agencies for both drug and MDs.
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OBJECTIVES: The objectives of this paper are to present the current status of HTA
in the field of radiology and describe the role played by Chilean Health System
governmental institutions and private agents in the decision-making process in
order to allocate resources for the incorporation of new technology. METHODS: A
bibliographical review was made based on the opinions of local experts, and a
review of the available local literature. RESULTS: The decision-making process of
acquiring a new technology in radiology is different depending on whether the
provider is public or private. For public providers, first, the hospital solicits to
include the purchase of the equipment in the budget for the year immediately
following. Then, the decision is taken by the Ministry of Health (MINSAL). It is a
centralized decision, but not subdue to a formal economic assessment. For private
providers, the decision usually comes from the clinical need. An economic assess-
ment for viability is carried out, expected demand and budgeted costs of examina-
tion are calculated in order to calculate the payback time on investment and finally
decision to purchase is made. CONCLUSIONS: Data on health economics are in-
creasingly important to the Chilean health authorities, even though, they are not
considered essential to make decisions. At present, there is more awareness of the
importance of implementing methods of analysis. Therefore, it is advisable to
continue providing such information. On the whole, the decision to purchase a new
technology in radiology depends on whether the provider is public or private. It
does not involve variables derived from complex economic or structured studies,
but depends on the need of the equipment and market availability.
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BENEFIT-RISK ANALYSIS IN ABSENCE OF CLINICAL EVIDENCE: DECIDING FOR
TREATMENT OF SKULL DEFORMITY IN BABIES AGED 5 MONTHS
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OBJECTIVES: Skull Deformaty (SD) is a flattening of the head as a result of pressure
on the malleable skull in infants in the first months of life. Presently, a RCT is
conducted to compare the effect of an orthotic helmet to the natural recovery of
skull shape in the first three years of life. Burden of treatment is considerable; the
helmet has to be worn 23 hours a day for at least 6 months. Possible harms include
acceptation problems, pressure wounds and severe skin rash or eczema. The
harms of treatment are perceived as an important reason for low adherence to and
parental refusal of helmet treatment. The objective of this study is to estimate the
risk-benefit trade-off in SD management in pediatric physiotherapists. METHODS:
A discrete choice experiment was performed with the most important attributes of
SD management. A total of 267 pediatric physiotherapists stated their preference
for treatment of a 5 month old child with SD. A three scenario design was chosen
Each scenario was characterized by its effect, its burden and the harms of treat-
ment. Logistical regression analysis was performed to analyze the results of the
discrete choice experiment. RESULTS: Not surprisingly, child physiotherapists’
ideal treatment has a high probability of timely success with low burden and min-
imal harms. At present, most attributes indicate a strong preference for awaiting
natural recovery. Risk benefit assessment favoring the helmet will only be attained
if the helmet can show highly significant clinical benefit. CONCLUSIONS: This
study shows that risk benefit analysis can give early indications on the potential of
a treatment, by estimating the effectiveness at which the treatment becomes more
favorable than its comparator. Whether the risk-benefit analysis will be in favor of
helmet treatment in the case of SD, is questionable, as earlier studies have not
demonstrated superiority of the helmet.
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AN EVALUATION OF THE NON-INVASIVE IMAGING TESTS USED IN CURRENT
CARE OF TIA AND MINOR ISCHEMIC STROKE IN THE NETHERLANDS: HOW
MUCH PRACTICE VARIATION IS THERE?
Buisman L, Silitonga A, Rijnsburger A, Redekop W
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: There is increasing interest in estimating the health and economic
impact of a new technology in the early phases of its development. However, this
requires knowledge about current care. We examined how non-invasive imaging is
currently used to assess carotid stenosis in patients with a recent TIA or minor
ischemic stroke, as a first step in an early economic evaluation of new imaging
technologies which will be used for the prediction of the risk of plaque rupture.
METHODS: We first examined the current guidelines in the The Netherlands, Eu-
rope and US regarding the use of non-invasive imaging tests (i.e. CT angiography
(CTA), duplex ultrasonography (DUS), MR angiography (MRA)) in the assessment of
carotid stenosis in patients with a TIA or minor ischemic stroke. In addition, semi-
structured interviews were conducted with neurologists in several Dutch hospitals
to determine how patients are actually diagnosed in daily clinical practice.
RESULTS: Current guidelines differ in the use of non-invasive imaging tests in
assessing carotid stenosis in patients with a recent TIA or minor ischemic stroke. In
addition, practice variation is high, since hospitals use different (combinations of)
tests. According to the neurologists, these differences are probably caused by ca-
pacity problems, degree of expertise in performing certain tests and lack of evi-
dence regarding effectiveness and cost-effectiveness of the imaging tests in assess-
ing carotid stenosis. CONCLUSIONS: The observed practice variation is high, and
has implications for assessing the health and economic impact of the new tech-
nology, since estimating impact requires comparison with current care. The choice
of just one comparator representing current care is therefore meaningless, since
choice of comparator may strongly affect the estimated health and economic im-
pact of the new technology. The final impact of a new technology will be hospital-
dependent, and therefore multiple comparisons and scenario analyses are needed.
Medical Device/Diagnostics – Research On Methods
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PATIENT DEMOGRAPHICS AND SURGICAL EXPENDITURE IN HERNIA REPAIR
SURGICAL COHORTS USING A RETROSPECTIVE NATIONWIDE PATIENT
DATABASE
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OBJECTIVES: Several observational studies have examined the epidemiological
and social characteristics of patients undergoing hernia surgery, but conclusions
drawn from these studies are generally limited due to the small sample population.
Here we describe patient demographics of hernia repair patients and surgical ex-
penditure using a population-based approach with a retrospective nationwide
database. METHODS: Premier Inc has established one of the largest hospital data-
bases worldwide. It collects patient data from around 500 hospitals in the US.
Hernia surgery was stratified by inpatient or outpatient treatment, hernia repair
surgery type (inguinal, incisional or umbilical), surgical procedure (laparoscopic or
open), and the type of mesh used (flat, tissue-separating or device). Patient demo-
graphics were recorded and are presented for every cohort of patients. Surgical
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costs across hernia repair and mesh type cohorts are also presented. RESULTS:
Across treatment groups the majority of patients were white (70%) with a mean
age of 54 years. Inguinal and umbilical hernia repair groups were both predomi-
nantly male with low to moderate incidences of obesity and diabetes. Incisional
hernia repair patients had the highest incidence of obesity (19.0%) and diabetes
(18.5%) and could be equally either male (42.0%) or female (58.0%). Tissue-separat-
ing mesh (TSM) was used mainly in incisional hernia repairs, whilst other meshes
were used in all surgical cohorts. TSM was used more frequently in females (60.1%)
and in patients with a high incidence of obesity (22.7%) and diabetes (22.1%). No
striking differences in surgical costs across the hernia repair or mesh type cohorts
were observed, with average surgical costs between $2199 and $4099.
CONCLUSIONS: This is the first example of extracting hernia repair patient demo-
graphics from a nationwide database. Although there are limitations to the inter-
pretation of this data, these results are encouraging. Further development of the
management, analysis and interpretation of such data is ongoing.
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DECISION ANALYTIC MODELS USED IN ESTIMATING THE COST-
EFFECTIVENESS OF DRUG-ELUTING STENTS VERSUS BARE-METAL STENTS
Burgers LT, Redekop W, Severens JL
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OBJECTIVES: Drug-eluting stents (DES) and bare-metal stents (BMS) are both used
widely in percutaneous coronary interventions (PCI). However, the incremental
cost-effectiveness of DES versus BMS varies considerably between studies. A sys-
tematic review is performed to gain insight how modeling influences the cost-
effectiveness of DES versus BMS. METHODS: We reviewed modeling studies pub-
lished until February 2011 that studied the cost-effectiveness of DES versus BMS.
We then extracted various parameters (e.g., model type, time horizon, data
sources, choice of disease states) and explored the influence of these parameters
on the cost-effectiveness outcomes. RESULTS: The incremental cost-effectiveness
ratios (ICER) from the 22 eligible studies ranged from DES being dominated by BMS
to DES being dominant. Different parameters can contribute to these differences,
including time horizon, assumptions concerning stent efficacy, study perspective,
stent cost prices and the specific type of stents being compared. Almost half of the
studies used a time horizon 12 months, assuming that differences in clinical
events between the two stents occur in the first year. However, published literature
contradicts this assumption since DES can induce very late in-stent thrombosis.
Moreover, many studies base restenosis rates on angiographic follow-up. Since
angiography overestimates the difference in restenosis rate between DES and BMS,
its use leads to an overestimate of quality-adjusted life-years gained and number of
avoided reinterventions and an underestimate of the costs of the DES strategy. The
price premium of DES versus BMS differs considerably between studies (€900-
€3300) and this difference also affects the ICER. CONCLUSIONS: Choices made in
cost-effectiveness models to compare DES with BMS lead to wide variation in cost-
effectiveness estimates, making it difficult to conclude that DES is more cost-effec-
tive than BMS. Since 80,000 PCIs are performed per year in the UK, it is very impor-
tant to obtain valid estimates of the cost-effectiveness of DES versus BMS.
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DRUG ELUTING BALLOON FOR THE TREATMENT OF PERIPHERAL ARTERY
DISEASE: A COST-EFFECTIVENESS ANALYSIS IN ITALY
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OBJECTIVES: Conventional balloon angioplasty for treatment of femoropopliteal
arterial disease is associated with a high restenosis rates 12 months post-proce-
dure. Recent clinical data have showed that use of DEBs may substantially reduce
restenosis. This suggests that DEB may decrease number of revascularizations and
therefore be a cost-effectiveness treatment for peripheral artery disease (PAD).
This study evaluated the economic impact of using a drug-eluting balloon (DEB) for
treatment of femoropoliteal arterial disease. METHODS: A decisional tree model
has been developed to compare two alternative treatment strategies for superficial
femoral artery disease (SFA): standard balloon angioplasty (PTA) and provisional
stenting versus DEB. Cost for initial hospital care and the long term management of
the disease, including reintervention, has been accounted for according to National
Health Care Service and societal perspectives. Probabilities have been retrieved by
available literature review of RCT and from an observational study on DEB that
evaluated risk of target lesion revascularization (TLR) at 1 year. Uncertainty around
the model inputs was tested using unvaried and multivariate sensitivity analyses
RESULTS: Specific procedure costs (including angioplasty balloon, DEB, stent, con-
trast medium) were 1500€ in both group because incremental cost for use of DEB
was offset by reduction of number of stents used in the DEB arm. No difference has
been noted also for initial hospitalization. Given a 1 year TLR rate of 8.7% and 14%
for DEB and stenting respectively, DEB resulted a cost-saving strategy for the treat-
ment of superficial femoral artery disease. Results were sensitive to hypothesis on
number of stents and DEB used and their relative cost. CONCLUSIONS: PTA of
femoropopliteal arterial disease using DEB appears to be a clinical improvement for
treatment of PAD and a potentially cost saving strategy compared to use of stents
in the Italian Health Care System.
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EFFECTIVENESS OF A HIGH DEFINITION CT SCANNER IN A CORONARY ARTERY
DISEASE POPULATION: A NICE DIAGNOSTIC GUIDANCE PROJECT
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OBJECTIVES: Cost-effectiveness analysis (CEA) of a medical test can require exten-
sive modeling if test results influence treatment decisions and disease progression.
We applied the assessment hierarchy of Schaafsma et al. (2009) to a CEA of a high
definition CT-scanner (one of the first assessments in the NICE/UK Diagnostics
Guidance Programme). METHODS: Schaafsma presents four steps to evaluate the
value of diagnostic tests: 1:accuracy assessment, 2:evaluation of added value,
3:clinical outcome assessment and 4:cost-effectiveness analysis. RESULTS: In the
assessment of diagnostic tests in coronary artery disease (CAD) modeling was
unavoidable, since a major problem in CEAs is the unavailability of randomized
controlled trials (RCT) that capture diagnosis, prognosis and treatment. Moreover,
most RCTs in the field of diagnostic test yield only information about sensitivity,
specificity, and short-term complication rates. When the evaluation is limited to
the added value of the high definition CT-scanner, one model, estimating the pro-
portions correctly diagnosed and complications associated with the CT-scanner, is
sufficient. However, since incorrect test results can result in major health loss
through incorrect or delayed treatment this method is inappropriate. Most tests
aim to improve prognosis thus, step 3 and 4 were applied in our assessment. There-
fore, five existing models were combined (diagnosis, CAD management, stroke
complication, radiation, non-CAD mortality) to create a meta-model that estimates
the cost-effectiveness. CONCLUSIONS: CEAs of a medical test can be performed in
various ways described by Schaafsma. If the aim is to conduct a comprehensive
analysis that includes various economic and health impacts, a synthesis of existing
models to create a meta-model is one way to achieve this. These models need to be
grafted together carefully to avoid invalid or irrelevant results; literature and ex-
pert opinion can assist in that endeavour. One critical pitfall is the use of models
created for dissimilar patient populations.
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ASSESSING COST EFFECTIVENESS AND VALUE OF FURTHER RESEARCH WHEN
DATA ARE SPARSE: NEGATIVE PRESSURE WOUND THERAPY FOR SEVERE
PRESSURE ULCERS
Soares MO
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OBJECTIVES:Health care resources are scarce and decisions have to be made about
how to allocate funds. Often these decisions are based on sparse or imperfect
evidence. One such example is negative pressure wound therapy (NPWT), which is
a widely used treatment for severe pressure ulcers; however, there is currently no
robust evidence that it is effective or cost effective.METHODS: This work considers
the decision to adopt NPWT given a range of alternative treatments, using a deci-
sion analytic modelling approach. Literature searches were conducted to identify
existing evidence on model parameters. Given the limited evidence base, a second
source of evidence, beliefs elicited from experts, was used. Judgements from ex-
perts on relevant (uncertain) quantities were obtained through a formal elicitation
exercise. Additionally, data derived from a pilot trial were also used to inform the
model. The three sources of evidence were collated, and the impact of each on cost
effectiveness was evaluated. RESULTS: Negative pressure wound therapy was ex-
pected to be less costly and more effective than any other treatments. The decision
to adopt NPWT was however very uncertain (probability of being cost effective of
0.55). The expected value of perfect information for the relevant UK population was
approximately £98 million. Specifically, the results suggest that a study evaluating
the effectiveness of NPWT might be worthwhile. The trial design that offered most
value was a three armed trial, with follow-up of at least 1 year and approximately
500 participants per arm. CONCLUSIONS: The analyses presented demonstrate
how allocation decisions about medical technologies can be explicitly informed
when data are sparse and, how this kind of analyses can be used to guide future
research prioritisation, not only indicating whether further research is worthwhile
but what type of research is needed and how it should be designed.
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SLEEP QUESTIONNAIRES DISCRIMINATE BETWEEN PARTICIPANTS WITH AND
WITHOUT OVERACTIVE BLADDER SYMPTOMS
Margolis MK1, Coyne K1, Jumadilova Z2
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OBJECTIVES: Nighttime urinary frequency (nocturia), common in patients with
overactive bladder (OAB), negatively impacts sleep quality. Three sleep-related
patient-reported questionnaires were assessed with regard to ability to discrimi-
nate between patients with and without OAB. METHODS: Adult men and women
with OAB symptoms for at least 3 months (8 micturitions per day;2 micturitions
per night; and6 urgency episodes over 3 days per bladder diary) and without OAB
symptoms (control group) completed several sleep questionnaires: Stanford Sleep-
iness Scale (morning and evening for 5 days), Epworth Sleepiness Scale, and Noc-
turia Quality of Life Questionnaire (N-QoL); t tests were performed between groups.
RESULTS: A total of 43 participants with OAB and 10 healthy controls were en-
rolled. Mean age and proportion of men were similar in the OAB and control groups
(63.7 vs. 55.6 years old [P0.31], and 46.2% vs 40.0% male [P0.53], respectively).
Race, employment status, and education level were also similar between groups
(all P0.25). Mean scores on the Stanford Sleepiness Scale across the 5 days were
significantly higher in the OAB group than the control group at time of awakening
(3.0 vs. 2.0; P0.0030) and at 7:00 pm (3.5 vs. 1.9; P0.0006), indicating greater
sleepiness. Epworth Sleepiness Scale mean scores were also significantly higher in
the OAB group than the control group (10.5 vs 4.1, respectively; P0.0001), indicat-
ing greater daytime sleepiness. On the N-QoL, participants with OAB had signifi-
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